Main description:

Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodies and approaches for their reversal. Anti-CD20 antibodies are used to achieve B cell depletion and are developed to treat B cell proliferative disorders, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In the past two decades, anti-CD20 antibodies have revolutionized the treatment of all B cell malignancies, however, there are patients that fail to respond to initial therapy or relapse sooner. This book explores new and existing avenues surrounding Anti-CD20 antibodies.

In recent years, several next-generation anti-CD20 therapies have been developed but predicting and reversing resistance is still a challenging task. These areas are being actively studied as they represent a potential to improve anti-CD20 therapies and are discussed thoroughly in the book.

It is a valuable resource for researchers, students and member of the biomedical and medical fields who want to learn more about resistance to anti-CD20 antibodies and their reversal.

Contents:

1. Anti-CD20 antibody treatment for B cell malignancies 2. Anti-CD20 antibody treatment for chronic lymphocytic leukemia 3. Rituximab and the new anti-CD20 antibodies 4. Rituximab versus obinutuzumab 5. Treatment options for rituximab-refractory patients 6. Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies 7. The type II anti-CD20 antibody obinutuzumab in combination with chemotherapy enhances direct cell death in resistant non-Hodgkin's lymphoma 8. Apply CD20 cross-linking amplification to overcome rituximab resistance 9. A comprehensive overview on the genetic alterations and molecular mechanisms of therapy resistance to anti-CD20 antibody 10. High FCGR2B expression has prognostic value in anti-CD20 antibodies-treated patients with diffuse large B cell lymphoma 11. FOXO1 promotes resistance of non-Hodgkin lymphoma to anti-CD20-based therapy 12. Targeting PDK4 has the potential to overcome rituximab resistance in diffuse large B cell lymphoma 13. STING activation reverses lymphoma-mediated resistance to anti-CD20 antibody immunotherapy 14. Reversal of resistance to anti-CD20 antibody therapies via targeting intracellular resistant factors 15. CTLA-4 blockade to overcome the resistance to anti-CD20 in advanced B cell lymphoma 16. Effect of anti-CD20 antibodies in combination with myeloid checkpoint blockade 17. Clinical efficacy of anti-CD20 antibodies in autoimmune diseases